Park Place Capital’s Standard BioTools LAB Stock Holding History

Park Place Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,808	Closed	-$8.14K	–	954
2023 Q3	$8.14K	Hold	2,808	–	–	﹤0.01%	792
2023 Q2	$5.42K	Hold	2,808	–	–	﹤0.01%	858
2023 Q1	$5.48K	Hold	2,808	–	–	﹤0.01%	854
2022 Q4	$3K	Buy	+2,808	New	+$3.46K	﹤0.01%	907

Other funds holding LAB

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Park Place Capital's LAB Position: Q4 2023 in Review

Park Place Capital sold out of Standard BioTools (LAB) in Q4 2023, closing a stake of 2,808 shares — an estimated $8.14K sold.

Park Place Capital first reported a position in LAB in Q4 2022 and held it in 4 quarters. The position peaked at $8.14K in Q3 2023. 86 funds tracked by Wall St. Rank hold LAB as of Q4 2023.

Park Place Capital reported no remaining Standard BioTools position as of Q4 2023 after selling out during the quarter.
Park Place Capital sold 2,808 Standard BioTools shares in Q4 2023, an estimated $8.14K.
Park Place Capital first reported a position in Standard BioTools in Q4 2022 and held it in 4 quarters.
Park Place Capital's Standard BioTools position peaked at $8.14K in Q3 2023.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2023.

Based on Park Place Capital's 13F filing for Q4 2023, filed 24 Jan 2024.